Research has focused primarily on the functional deregulation of the androgen receptor (AR); AR signaling is pivotal in the development of potent ADT drugs, such as abiraterone acetate and enzalutamide, for the treatment of PCa patients [10]. Here, AR is linked to posterior cortical atrophy.